Retrieved on:
Wednesday, January 17, 2024
The study shows that wilate® prophylaxis is highly effective at reducing bleeding rates in children and adults with all types of VWD and across examined bleeding sites.
Key Points:
- The study shows that wilate® prophylaxis is highly effective at reducing bleeding rates in children and adults with all types of VWD and across examined bleeding sites.
- The results provide compelling evidence for the use of regular prophylaxis in people with VWD.
- "The new data from the WIL-31 study provide strong evidence for the use of wilate® prophylaxis in people with all types of VWD.
- In such instances, indirect treatment comparisons can be used to compare the effects of different treatments.
Retrieved on:
Tuesday, October 31, 2023
Haemophilia,
Factor VIII,
European Journal,
PROPEL,
PROTECT,
Exercise,
Georgetown University Medical Center,
VIII,
Georgetown Lombardi Comprehensive Cancer Center,
Efmoroctocog alfa,
Patient,
Pharmaceutical industry,
Dentistry The analysis used data from prospective clinical trials of personalised prophylaxis in adults with severe haemophilia A.
Key Points:
- The analysis used data from prospective clinical trials of personalised prophylaxis in adults with severe haemophilia A.
Dr Kessler commented, "This MAIC exercise provides important comparative data on the efficacy and consumption of various recombinant FVIII products in adults with haemophilia A on personalised prophylaxis.
- The results can be considered by clinicians and patients when treatment decisions are being made."
- MAICs are a way of comparing the efficacy of different medical interventions or products in the absence of head-to-head randomised trials3.
- In addition, a short video summarising the results is available in the online version of the article.
Retrieved on:
Thursday, February 2, 2023
Chemicals,
Plastics,
Manufacturing,
Stem Cells,
Pharmaceutical,
Surgery,
Medical Devices,
Hospitals,
Clinical Trials,
Other Manufacturing,
Science,
Biotechnology,
Alternative Medicine,
Other Science,
Health,
Research,
Transfusion medicine,
Octapharma,
Patient,
Shock,
Trauma,
Temperature,
Hypothermia,
AB,
Survival,
Plasma,
TIC,
Metabolic acidosis,
Bleeding,
FFP,
Death,
Pharmaceutical industry,
Hospital Octapharma AG today announced that European medical authorities have approved the lyophilised presentation of the well-established octaplasLG® - pharmaceutically-licensed S/D treated plasma for transfusion.
Key Points:
- Octapharma AG today announced that European medical authorities have approved the lyophilised presentation of the well-established octaplasLG® - pharmaceutically-licensed S/D treated plasma for transfusion.
- The line extension, which will be marketed in Europe as a powder and solvent for solution for infusion, offers new and potentially life-saving treatment options in pre-hospital and emergency settings.
- Trauma results in 4.4 million deaths worldwide annually6, with uncontrolled bleeding being the major cause of potentially preventable death.
- Trauma-induced coagulopathy (TIC) is an early abnormal response characterised by hypocoagulation, in addition to acute blood loss, shock, hypothermia and metabolic acidosis, that begins soon after injury.
Retrieved on:
Wednesday, January 18, 2023
Treatment decisions need to consider the perspectives of both the patient and the clinician to find the ideal approach for each patient.
Key Points:
- Treatment decisions need to consider the perspectives of both the patient and the clinician to find the ideal approach for each patient.
- The interactive Octapharma symposium at the 16th Annual Congress of EAHAD in Manchester, UK, will present the perspectives of three clinicians and three patients on key treatment decisions encountered during the lives of people with haemophilia A.
- The three patients and their families will share their experiences, the challenges they have faced, and decisions that they have taken.
- "We appreciate the importance of bringing together the perspectives of both clinicians and people with haemophilia A in order to provide individualised care and improve the lives of patients."
Retrieved on:
Monday, February 22, 2021
Key Points:
- "Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study" https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-004... ).
- With enrolment of 110 patients, the NuProtect study was the largest clinical study to investigate a single product in true PUPs.
- These data complement the wealth of clinical experience in patients with haemophilia A receiving Nuwiq for the treatment and prevention of bleeding.
- Earlier this year the FDA approved the inclusion of the immunogenicity data from the NuProtect study in the Nuwiq Prescribing Information.
Retrieved on:
Monday, February 22, 2021
Key Points:
- "Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study" https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-004... ).
- With enrolment of 110 patients, the NuProtect study was the largest clinical study to investigate a single product in true PUPs.
- These data complement the wealth of clinical experience in patients with haemophilia A receiving Nuwiq for the treatment and prevention of bleeding.
- Earlier this year the FDA approved the inclusion of the immunogenicity data from the NuProtect study in the Nuwiq Prescribing Information.
